Complete Response Rates with Lenalidomide/Rituximab in the Front-Line Treatment of Indolent B-Cell Non-Hodgkin Lymphoma (NHL)
Complete Response Rates with Lenalidomide/Rituximab in the Front-Line Treatment of Indolent B-Cell Non-Hodgkin Lymphoma (NHL)
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Stephanie A Gregory, MD (6/18/10) and John P Leonard, MD (6/28/10)
Fowler NH et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin’s lymphoma. Proc ASCO 2010;Abstract 8036. |
||||||||